Skip to main content

TXG 10x Genomics, Inc.

Healthcare

70.11 Close 10/30
Since 2024-12-02 +325.7%
Open
73.65
High
75.79
Low
67.42
Prev close
81.55
Volume
5.2M
Amplitude
10.26%
P/B
11.0
Revenue YoY (TTM)
-4.3%
52W 12.44 102.81

Is 10x Genomics, Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Momentum: Strong; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Expensive.
TTM P/E -118.83 N/A
Price / book 11.04 93th percentile Expensive
Free-cash-flow yield (%) 1.33 52th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Neutral FCF margin, TTM is Good, but Operating margin, TTM is Average.
ROE, TTM (%) -9.1 31th percentile Average
Operating margin, TTM (%) -14.33 25th percentile Average
FCF margin, TTM (%) 19.68 76th percentile Good
Quality Factor Investing: A US Quality Value Backtest
Growth Neutral All 2 indicators are Average.
Revenue growth, TTM YoY (%) -4.28 28th percentile Average
Diluted EPS growth, TTM YoY (%) -15.71 48th percentile Average
Momentum Strong All 2 indicators are Top.
60-day return (%) 53.75 98th percentile Top
240-day return (%) 341.22 100th percentile Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Neutral 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 308,768,540 95th percentile Top
60-day annualized volatility (%) 87.62 79th percentile Average
Factor Investing Explained: 10 Classic Factors in US Stocks

10x Genomics, Inc. (TXG) today

1 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From 10x Genomics, Inc. to every stock like it

AI finds several complementary traits of 10x Genomics, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like 10x Genomics, Inc.

10x Genomics, Inc. (TXG) peers and tracking

Watchlist

This page refreshes daily after the close. Add 10x Genomics, Inc. to your watchlist to track signal changes on your next visit.

10x Genomics, Inc. (TXG) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 99.83%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
15 historical occurrences (since 2020-03-13)

Average forward return after Top-quintile 6-month momentum

20-day: Win 60%, Sample 15, Median +6.98%, Excess +4.49%, Beat mkt rate 60%

60-day: Win 80%, Sample 15, Median +20.36%, Excess +18.31%, Beat mkt rate 80%

120-day: Win 78.6%, Sample 14, Median +27.41%, Excess +30.4%, Beat mkt rate 64.3%

120 days after: historical avg +41.59%

20-day +5.69%
60-day +23.63%
120-day +41.59%
20-day
60-day
120-day
Win
60%
80%
78.6%
Sample
15
15
14
Median
+6.98%
+20.36%
+27.41%
Excess
+4.49%
+18.31%
+30.4%
Beat mkt rate
60%
80%
64.3%

Over 14 occurrences, 120-day forward avg gained 41.59%, beat the market by 30.4 pts; win rate 78.6%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

12 times historically; 60-day forward avg +21.26%, win rate 58.3%, beating the market by +17.66 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

7 times historically; 60-day forward avg -14.97%, win rate 28.6%, beating the market by -18.65 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

15 times historically; 60-day forward avg +17.74%, win rate 60%, beating the market by +14.45 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.